Wednesday, June 26, 2019 11:12:42 AM
Posted by Jeshia Costen on Jun 26th, 2019 // Comments off
?TrovaGene Inc (NASDAQ:TROV) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 621,000 shares, a decline of 12.0% from the April 15th total of 705,900 shares. Currently, 12.0% of the company’s stock are short sold. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 0.5 days.
An institutional investor recently raised its position in TrovaGene stock. Vanguard Group Inc. grew its stake in shares of TrovaGene Inc (NASDAQ:TROV) by 508.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 239,029 shares of the medical research company’s stock after acquiring an additional 199,767 shares during the period. Vanguard Group Inc. owned about 1.04% of TrovaGene worth $195,000 at the end of the most recent quarter. 6.04% of the stock is owned by hedge funds and other institutional investors.
Get TrovaGene alerts:
Shares of NASDAQ:TROV opened at $2.48 on Wednesday. The company has a 50-day simple moving average of $2.93. TrovaGene has a one year low of $2.43 and a one year high of $9.65. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $12.45 million, a PE ratio of -0.30 and a beta of 0.90.
TrovaGene (NASDAQ:TROV) last announced its earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.05. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%. The business had revenue of $0.16 million during the quarter. On average, equities research analysts forecast that TrovaGene will post -4.02 earnings per share for the current fiscal year.
A number of equities analysts recently commented on TROV shares. ValuEngineupgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Noble Financial set a $20.00 target price on shares of TrovaGene and gave the stock an “outperform” rating in a research note on Friday, March 8th. Maxim Group reiterated a “buy” rating and set a $8.00 target price on shares of TrovaGene in a research note on Thursday, March 7th. Finally, Zacks Investment Researchupgraded shares of TrovaGene from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Tuesday, March 12th.
TrovaGene Company Profile
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.
Recent CRDF News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:55 PM
- Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:13 PM
- Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 10:10:38 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:06:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:03:35 PM
- Cardiff Oncology to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:05:00 PM
- Cardiff Oncology to Present at Upcoming Investor Conferences in May • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:40 PM
- Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:07:00 PM
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC • GlobeNewswire Inc. • 02/29/2024 09:06:00 PM
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:00:21 PM
- Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:01:34 PM
- Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research • PR Newswire (US) • 01/17/2024 03:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM